» Articles » PMID: 23796936

Determination of Activities of Solithromycin at Different PHs and Its Intracellular Activity Against Clinical Isolates of Neisseria Gonorrhoeae from a Laboratory Collection

Overview
Specialty Pharmacology
Date 2013 Jun 26
PMID 23796936
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

We evaluated the activity of solithromycin against 196 clinical gonococcal isolates collected at the Public Health Ontario Laboratories, Toronto, Canada, including isolates with different levels of azithromycin resistance, as well as the role of pH in MIC determinations using pH-adjusted agar plates (pH range, 5.6 to 7.6). invasion assays were performed using monolayers of HeLa epithelial cells and clinical gonococci displaying different azithromycin MICs; infected cultures were treated with solithromycin, and its intracellular activity was determined by CFU assays after 3 and 20 h of exposure. Solithromycin displayed a MIC and MIC of 0.0625 and 0.125 μg/ml, respectively, making its activity at least 4-fold higher than that of azithromycin. Clinical isolates with elevated MICs for azithromycin (MICs of ≥2,048 μg/ml and 4 to 8 μg/ml) showed solithromycin MIC values of 8 and 0.5 μg/ml, respectively. In contrast to azithromycin, solithromycin MICs were not significantly affected by acidic pHs, suggesting more stability at lower pH. Moreover, when intracellular isolates were incubated with solithromycin at 4 times, 1 times, and one-fourth of the MIC, the exposure to solithromycin resulted in the progressive loss of viability of most isolates over time. The intracellular activity of solithromycin, combined with the low MICs to this agent, indicates that it may be an attractive option for gonorrhea treatment if clinical trials in development reveal that this drug can be used safely in adult indications, especially when multidrug-resistant clinical isolates are now emerging.

Citing Articles

Molecular Mechanisms of Drug Resistance and Epidemiology of Multidrug-Resistant Variants of .

Mlynarczyk-Bonikowska B, Kowalewski C, Krolak-Ulinska A, Marusza W Int J Mol Sci. 2022; 23(18).

PMID: 36142410 PMC: 9505821. DOI: 10.3390/ijms231810499.


Antibacterial Activity of Chitosan Nanoparticles Against Pathogenic .

Alqahtani F, Aleanizy F, El Tahir E, Alhabib H, Alsaif R, Shazly G Int J Nanomedicine. 2020; 15:7877-7887.

PMID: 33116506 PMC: 7568623. DOI: 10.2147/IJN.S272736.


Repurposing salicylamide for combating multidrug-resistant .

Alhashimi M, Mayhoub A, Seleem M Antimicrob Agents Chemother. 2019; 63(12).

PMID: 31570391 PMC: 6879211. DOI: 10.1128/AAC.01225-19.


A New, Potent, and Placenta-Permeable Macrolide Antibiotic, Solithromycin, for the Prevention and Treatment of Bacterial Infections in Pregnancy.

Keelan J, Payne M, Kemp M, Ireland D, Newnham J Front Immunol. 2016; 7:111.

PMID: 27066004 PMC: 4817400. DOI: 10.3389/fimmu.2016.00111.


Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.

Jamieson B, Ciric S, Fernandes P Antimicrob Agents Chemother. 2015; 59(8):4379-86.

PMID: 25870056 PMC: 4505280. DOI: 10.1128/AAC.04652-14.


References
1.
Barry A, Fuchs P . In-vitro potency of azithromycin against gram-negative bacilli is method-dependent. J Antimicrob Chemother. 1991; 28(4):607-10. DOI: 10.1093/jac/28.4.607. View

2.
Faur Y, Weisburd M, Wilson M, May P . A new medium for the isolation of pathogenic Neisseria (NYC medium). I. Formulation and comparisons with standard media. Health Lab Sci. 1973; 10(2):44-54. View

3.
Unemo M, Fasth O, Fredlund H, Limnios A, Tapsall J . Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009; 63(6):1142-51. DOI: 10.1093/jac/dkp098. View

4.
Newman L, Moran J, Workowski K . Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007; 44 Suppl 3:S84-101. DOI: 10.1086/511422. View

5.
Unemo M, Golparian D, Limnios A, Whiley D, Ohnishi M, Lahra M . In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?. Antimicrob Agents Chemother. 2012; 56(7):3603-9. PMC: 3393402. DOI: 10.1128/AAC.00326-12. View